doi:10.1016/j.jtho.2020.04.028Shugeng GaoNing LiShuhang WangFan ZhangJie HeJournal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors....
Mericka. 1st Chest Clinic and Oncological Clinic 1st Faculty of Medicine, Prague, Radiotherapeutic Institute, 2nd Faculty of Medicine, Prague, Czech Republic DOI: http://dx.doi.org/10.1016/0169-5002(94)94019-3Abstract Images/Data Related Articles To view the full text, please login as a ...
In a previous study, the authors suspected that exposure to fumes from cooking oils was an important risk factor for lung cancer in Taiwanese women nonsmokers in the Republic of China. In a new case-control study conducted in 1993–1996, they further explored the association of oil fumes ...
A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cance...
摘要: Discusses the of the paper 'Declining lung cancer rates among young men and women in the United States,' by Susan S. Devesa and colleagues, which appeared in a 1989 issue of the 'Journal of the National Cancer Institute.'关键词:...
Chen XZ. Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China. JAMA Oncol. 2019;5(1):116–7. PubMed Google Scholar Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients wit...
This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be ...
We used ASRs from the following cancer registries, the United States of America, Beijing in China, Mumbai in India, Hiroshima and Osaka in Japan, the Republic Korea, Gironde in France, Hamburg in Germany, the United Kingdom and Australia from the CI5-XI database. Year at cancer diagnosis ...
Tongji University School of Medicine, Shanghai, People's Republic of China Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been demonstrated to improve responses and clinical outcomes significantly in patients with advanced non-small-cell lung cancer (NSCLC). ...